Formulation Development & Technology
MSN Laboratories investment in finished dosage research and development began in 2003 in Hyderabad. The company’s goal was to utilize their technological resources to develop products concurrently with our API research and development team. Our fully integrated R&D facility was completed in 2012.
Our five-acre R&D campus has over 750,000 square feet of completed facility space. The R&D facility has approximately 1,100 scientists developing generics, using innovative technology to generate first to market and high barrier of entry products. The R&D facility is certified to CGMP standards and has been subject to an FDA approval.
Our research competence is also complemented by the expertise of our Intellectual Property team. This highly experienced group has a strong core competency in patent law and regulatory filings. They have successfully filed sixteen Paragraph 4, first to market products, fueling the growth our pipeline with high value generics.